In Episode #018 I explore the economics behind the Netflix subscription model, its advantages when applied to Healthcare and Big Pharma, as well as its potential downsides. Is the Netflix model even working for Netflix?

Chapters

* (0:00) Introduction

* (0:35) What is the Netflix Model for Drugs?

* (1:57) The Netflix model for Hepatitis C drugs

* (3:54) Netflix stock takes a tumble

* (5:27) Hollywood strikes and Netflix

* (7:38) How Netflix spends and saves its money

* (8:37) NHS saves 7 billion pounds

* (11:24) What Big Pharma thinks about these savings

* (14:58) Adobe is vulnerable to disruption because of Netflix

* (18:17) Responding to viewer comments

Show Notes

* Netflix style subscription model for drugs in Big pharma

* Computer modelling for Pricing License Agreement (PLA/Netflix) in Hep C study

* Subs surged but stock tanked for Netflix

* How the Hollywood strikes are affecting Netflix

* Everything Netflix is cancelling

* Expensive Netflix Shows

* VPAS for UK saves 7 billion

* What does Big pharma think?

Thanks for reading BioLab Collective with Jack Wang! Subscribe for free to receive new posts and support my work.

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit biolabcollective.substack.com